FDA Approves Ocrevus Zunovo. A Twice-A-Year Subcutaneous Injection for People With Relapsing and Progressive Multiple Sclerosis
Genentech, announced the U.S. Food and Drug Administration (FDA) approved Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).
- Ocrevus Zunovo is the first and only twice-a-year, healthcare professional (HCP) administered approximately 10-minute subcutaneous (SC) injection approved for both these forms of multiple sclerosis, giving people living with MS more treatment options.
- Ocrevus Zunovo gives patients and providers another option for receiving Ocrevus, with a decade of treatment for multiple sclerosis.
Source: Genentech
